Sign In
Buy NERV
$4.68
-0.0700 (-1.47%)
At Close: Jun 03, 2026
New York, New York--(Newsfile Corp. - December 9, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities
LOS ANGELES--(BUSINESS WIRE)---- $NERV #NERV--SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Minerva Neurosciences, Inc.
Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Minerva Neurosciences, Inc. – NERV
11:59am, Wednesday, 09'th Dec 2020
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Minerva Neurosciences, Inc. (N
LOS ANGELES--(BUSINESS WIRE)---- $NERV #NERV--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Minerva Neurosciences, Inc.
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Minerva Neurosciences, Inc. (NERV)
09:51am, Wednesday, 09'th Dec 2020
NEW YORK, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Minerva Neurosciences, Inc. (“Minerva” or the “Company”) (NAS
A Potential Trade Arises On Minerva
12:01am, Wednesday, 09'th Dec 2020
NERV had a chat with the FDA, the market didn't like the details. The phase 3 study might actually have succeeded, based on a modified intent-to-treat analysis.
NEW YORK--(BUSINESS WIRE)-- #Classaction--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States Di
LOS ANGELES--(BUSINESS WIRE)---- $NERV #NERV--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Minerva Neurosciences, Inc.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Minerva Neurosciences, Inc. - NERV
08:16pm, Monday, 07'th Dec 2020
NEW YORK, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Minerva Neurosciences, Inc. (“Minerva” or the “Company”) (NASDAQ: NERV). Such inves
Minerva Neurosciences Announces Outcome of Type C Meeting with FDA and Next Steps in the Development of Roluperidone
08:00am, Tuesday, 01'st Dec 2020
WALTHAM, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervou
Minerva Neurosciences to Present at Jefferies Virtual London Healthcare Conference
08:30am, Monday, 09'th Nov 2020
WALTHAM, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat cen
Minerva Neurosciences, Inc.'s (NERV) CEO Remy Luthringer on Q3 2020 Results - Earnings Call Transcript
12:06pm, Monday, 02'nd Nov 2020
Minerva Neurosciences, Inc.'s (NERV) CEO Remy Luthringer on Q3 2020 Results - Earnings Call Transcript
Minerva Neurosciences Reports Third Quarter 2020 Financial Results And Business Updates
07:30am, Monday, 02'nd Nov 2020
WALTHAM, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervou
Minerva Neurosciences to Report Third Quarter 2020 Financial Results and Business Updates on November 2, 2020
08:30am, Monday, 26'th Oct 2020
Management to host conference call Management to host conference call
Minerva Neurosciences to Present at JMP Securities CNS Forum
12:00pm, Thursday, 13'th Aug 2020
WALTHAM, Mass., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat cen
